Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy.
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Lefitolimod (Primary)
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms IMPACT
- Sponsors Mologen
- 07 Jun 2017 Biomarkers information updated
- 29 May 2015 Results of a subgroup analysis on overall survival were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2013 Final results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History